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The gastrointestinal tract and HIV pathogenesis
Introduction
Gastrointestinal dysfunction has been recognised as a major 
manifestation of the human immunodeficiency virus (HIV) infection 
since the earliest recognition of the syndrome, the acquired 
immune-deficiency syndrome (AIDS). It was originally thought that 
these disease manifestations were the sequelae of the immune 
destruction which characterises AIDS, rather than it being central to 
the pathogenesis of AIDS. In the past decade, it has been observed 
that the mucosal immune system and the intestinal immune system 
are pivotal in the pathogenesis of AIDS, with the most critical 
events, namely transmission, viral amplication, and CD4+ T-cell 
destruction occurring in the gastrointestinal tract (GIT). Furthermore, 
the breakdown of the mucosal barrier with consequent microbial 
translocation, are considered to be major drivers of AIDS progression.1 
In this regard, the GIT mucosal tissue is not only a primary site of 
viral transmission, but also a major site of viral replication, CD4+ 
T-cell destruction, regardless of the route of transmission.1 
HIV enteropathy
GIT enteropathy in persons living with HIV (PLWH) can occur from 
the acute phase of infection, through to advanced disease. It is 
characterised by diarrhoea, increased GIT inflammation, increased 
intestinal permeability (up to fivefold higher than in healthy individuals), 
malabsorption of bile acids, and vitamin B
12. Histologically, the GIT 
enteropathy in HIV involves inflammatory infiltrates of lymphocytes 
and damage to the GIT epithelial layer (which includes villous atrophy, 
crypt hyperplasia and villous blunting). These pathological changes 
may occur in the absence of any detectable bacterial, viral or fungal 
enteropathogens, which are often associated with enteropathy.2 
HIV enteropathy was reported as early as 1984. 3
Although the mechanism(s) that cause the abnormalities in HIV 
enteropathy, are poorly understood, it has been suggested that 
HIV has a direct “virotoxic” effect on the enterocyte. It has been 
observed that the HIV accessory protein Tat has an inhibitory effect 
on glucose uptake in the enterocyte. HIV gp120 has been found 
to result in increased concentrations of calcium in the enterocyte, 
which is associated with tubulin depolymerisation, and a decrease 
in epithelial cells’ ability to maintain ionic balances. It has also been 
postulated that HIV may result in abnormal differentiation of the 
enterocyte, as it has been found to be in the proximity of abnormally 
enlarged enterocytes.2 
Local activation of the GIT immune system is also thought to 
play a role in HIV enteropathy. In HIV there are high levels of 
proinflammatory mediators such as beta chemokines interleukin-6 
(IL-6), interleukin-10 (IL10) and interferon (IFN-γ) found in the 
lamina propria of the colon in PLWH. The degree of inflammation has 
been found to correlate with the level of viral replication. Although 
systemic immune activation is a hallmark of HIV, the aetiology of the 
latter remains elusive. It has also been postulated that local bacterial 
translocation across the damaged tight epithelial barrier, results 
in microbial products that stimulate the immune system locally, 
presumably through receptors such as Toll-like receptors. A crucial 
consequence of induction of local inflammation through any means, 
is through HIV’s preferential infection of activated CD4+ T-cells, which 
in turn augments the HIV replication.2
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CD4+ T-cell destruction
Originally it was thought that HIV involved a period of latency, 
however, it is now well established that the HIV virus attaches to the 
CD4+ molecule on the T-cells and the monocyte and macrophage 
lineage cells, and on a chemokine receptor, during acute infection. 
The direct infection of CD4+ T-cells leads to the destruction of these 
cells and global immune deficiency, as these cells are required for 
induction and control of most immune responses. The infection of the 
monocyte and macrophage lineage cells appears to be particularly 
important in chronic HIV infection and are possibly major reservoirs 
for viral replication and persistence, and hence contributing to 
immune deficiency. 1 
More recently, it has been observed that the CD4+ T-cells which 
bear the CCR5 HIV co-receptor are the primary targets of HIV. The 
CD4+ T-cells with CCR5 receptors constitute the majority of the 
CD4+ T-cells. It is estimated that nearly eighty percent of the T-cell 
population is found in the GIT.3 
Depletion of the CD4+ T-cells involves the entire GIT.2 The largest 
number of mucosal memory CD4+ T-cells are found in the GIT, and 
significant depletion of these cells occurs in the first 17 days post 
HIV infection. In a recently postulated model (based on GIT biopsies), 
it is thought that the bulk of CD4+ T-cell depletion occurs in the first 
two to three weeks of acute infection.3
PLWH with a CD 4 count of less than 200 cells/uL, have been found to 
have a twofold increase in diarrhoea. The latter affirms the view that 
diarrhoea is an AIDS defining condition. A decrease in CD4+ T-cells 
(less than 200 cells/ uL) has been observed to be associated with 
intestinal parasitic infections, such as Cryptosporidium, I. belliand 
and S. Stercoralis), and with a higher incidence of diarrhoea.4
Th17 cell loss and impairment of mucosal integrity
HIV mediated loss of Th17 cells from the gut-associated lymphoid 
tissue (GALT) has been observed to impair mucosal integrity, and innate 
defence mechanisms against gut microbes. Th17 cells are important 
for intestinal homeostasis. Th17 cells are involved in epithelial 
regeneration, and stimulate the production of defensins and mucin, 
as well as induce the expression of claudins, which are components 
of epithelial tight junctions. The Th17 cytokine, interleukin-22 (IL-22) 
increases the production of the lipopolysaccharide binding protein 
(LBP) in the liver. Considering, the massive CD4+ T-cell depletion in 
the lamina propria after HIV infection, it is probable that Th17 cells 
are also depleted by HIV. Since Th17 cells have multiple roles in 
controlling epithelial integrity and microbial invasion, the depletion 
of Th17 is likely to affect the integrity of the GIT.5 To date, Salmonella 
has been directly shown to translocate across the GIT barrier, when 
Th17 cell function is compromised in the GALT, in PLWH.5
Impact of HIV infection on lactose absorptive capacity
It has been reported that lactose malabsorption is significantly higher 
(70%) in PLWH, than HIV-uninfected controls (34%). Furthermore, 
the degree of lactose malabsorption was found to be significantly 
greater in PLWH with advanced disease, versus those in the earlier 
stages of disease. The degree of lactose malabsorption was also 
related to whether PLWH were symptomatic and had intestinal 
manifestations, than asymptomatic PLWH and non-HIV infected 
controls. It is presumed that apart from the presence of the HIV, 
other factors (probably both structural and immune) determine 
the enterokinetic alterations responsible for lactase deficiency and 
lactose malabsorption.7
Clinical presentation of enteropathy
A high percentage of PLWH worldwide have been reported to 
initially present with, or develop, diarrhoea, irrespective of whether 
they are on HAART or not. In the United States, 50% of PLWH 
have presented with diarrhoea. However, in developing countries 
a prevalence of as many as 80% of PLWH have presented with 
diarrhoea. The presentation of diarrhoea may or may not be in the 
presence of an opportunistic infection of the GIT. The opportunistic 
infections that affect the GIT in PLWH include parasitic infections (for 
example: Cryptosporidia, Isopora and Cyclospora), viral [in particular 
Cytomegalovirus (CMV)], and bacterial [for example: Mycobacterium 
tuberculosis (TB), Salmonella, Shigella, Campylobacter jejuni and 
Mycobacterium avium complex (MAC)]. Prompt treatment of CMV is 
very important, as it is associated with a poor prognosis in PLWH 
and a high rate of recurrence. A person with GIT MAC usually has 
disseminated disease, a very low CD4+ T-cell count, and limited 
survival time. Since the introduction of HAART, the incidence and 
prevalence of MAC has decreased. TB of the GIT may affect immune-
compromised and immune-competent individuals. It is estimated that 
GIT TB accounts for 1 to 3% of TB cases worldwide. It is commonly 
found in the region of the ileocaecal valve, but can occur at any 
region throughout the GIT.6
 Clinical presentation of HIV-associated diarrhoea varies among PLWH 
depending on the principal section of the GIT that is involved. Small 
bowel diarrhoea tends to result in large bulky postprandial stools 
almost immediately after eating, and the individual may experience 
postprandial paraumbilical abdominal pain. However, if the affected 
individual fasts, the diarrhoea significantly decreases. Individuals 
with small bowel diarrhoea usually experience weight loss. Whilst 
individuals with large intestine diarrhoea (termed “colitic diarrhoea”) 
usually present with frequent, small-volume stools, and the stools 
may have visible blood and mucus. These individuals will usually 
experience lower-quadrant abdominal pain, and the sensation of 
rectal urgency. However, in many instances, it may be difficult to 
differentiate between small- and large bowel diarrhoea.6
Opportunistic infections are not limited to the small- and large bowel, 
and may occur in the upper GIT, including oesophageal pathology 
(for example: candida oesphagitis, CMV, and herpes simplex virus), 
and gastric and duodenal pathology (for example: CMV, Helicobacter 
pylori and cryptosporidium). These infections may lead to dysphagia 
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and hence poor nutritional intake but also recurrent dehydrating 
vomiting.8
Most of the GIT opportunistic infections described will result in further 
aggravation of HIV-associated enteropathy, due to structural damage 
and/or immune sensitisation; hence making it difficult to differentiate 
whether the severity of GIT related symptoms is due to HIV disease 
progression or the severity of other opportunistic infections. 
In a recently published study, Densupsoontorn et al (2009)9 reported 
that HIV-infected children with a higher severity of malnutrition and 
more advanced stages of HIV clinical symptoms, had accelerated 
whole gastrointestinal transit time. The authors recommended early 
nutritional intervention for children with severe malnutrition and 
advanced HIV disease with specialised lactose-free feeds of low 
osmolality to aid in delaying gastric GIT transit time and to allow for 
greater nutrient absorption. 
The role of gut in HIV disease progression
Immune activation in chronic HIV infection includes polyclonal B 
cell activation, increased turnover of T-cells, a high frequency of 
“activated” phenotype T-cells as well as increased levels of cytokines 
and other proinflammatory mediators. This activation results in the 
restoration of CD4+ T-cells and immunocompetence but the negative 
effects include lymph node fibrosis, thymic dysfunction, clonal 
exhaustion, drainage of memory T-cell pools and generation of more 
targets for HIV replication.3 
It has been speculated that due to the massive depletion of memory 
T-cells in the gut, as well as structural defects of the GIT lining, 
microbial translocation from the gut is probably involved in driving 
immune activation. It is thought that the gut-derived microbes or 
microbial products translocate to the systemic circulation in the 
absence of overt bacteremia.3 
Quantification of microbial translocation
Microbial translocation can be quantified by measuring plasma 
levels of lipopolysaccharide (LPS), the endoxin produced by 
bacteria that have translocated across the GIT lining. PLWH with 
acute HIV infection were found to have LPS levels similar to those 
of non-HIV infected individuals. However, in PLWH with chronic 
HIV infection, the LPS levels were significantly higher. In an earlier 
study, non-infected HIV individuals were injected with LPS produced 
systemic immune activation with increased levels of inflammatory 
cytokines [for example, tumour necrosis factor, interleukin (IL)-1 
receptor antagonist, IL6 and IL8] with plasma LPS levels as low as 
14 pg/ml. In studies on PLWH with chronic infection, the LPS levels 
were found to be 75 pg/ml; hence sufficient to stimulate systemic 
immune activation.3
It is well known that immune activation can be attenuated with potent 
antiviral therapy (ART), although the decline is much slower than HIV 
RNA levels and may remain elevated for a year after ART. It has been 
observed that statistically significant decreases in LPS levels only 
occur in PLWH after 48 weeks on ART. It is thus appears that ART is 
currently the most effective way to protect the gut, and help reduce 
bacterial translocation, and hence reduce chronic systemic immune 
activation.3 
Further evidence of the link between bacterial translocation and HIV 
pathogenesis was recently reported, in which PLWH who had HIV-
associated dementia were found to have higher plasma LPS levels 
when compared with PLWH without neurocognitive impairment. It 
has been proposed that LPS-mediated monocyte activation and 
trafficking to the brain may well be the underlying mechanisms of 
the association between LPS plasma levels (bacterial translocation) 
and HIV-associated dementia. 5 Recently published research findings 
also suggest that microbial translocation may be a fundamental 
mechanism by which the progression of hepatitis C-related liver 
disease may be accelerated to cirrhosis in PLWH.10
HAART and the gastrointestinal tract
Currently, ART has, in most cases, been found to reduce plasma 
viral loads to undetectable levels resulting in subsequent increases 
in peripheral blood CD4+ T-cells. Early studies of HIV-associated 
enteropathy after the initiation of ART documented significant 
decreases in GIT symptoms, namely, abdominal bloating, cramping 
and loose stools. However, a decrease in viral replication and CD4+ 
T-cell reconstitution does not occur at a similar rate at all anatomic 
sites, especially in the GIT. Recent studies have shown that in the 
small bowel CD4+ T-cell reconstitution was poor, and in PLWH with 
acute HIV infection who had been on highly active antiviral therapy 
(HAART) had a much greater reconstitution (twofold) of CD4+ 
T-cells when compared with individuals with chronic HIV infection 
(the latter individuals rarely ever reconstituted GIT CD4+ T-cells to 
normal levels). Importantly, it was also observed that although many 
PLWH treated with HAART reconstituted peripheral CD4+ T-cells, no 
HIV-infected individual ever reconstituted GIT CD4+ T-cells to levels 
observed in non-infected individuals.2 
GIT CD4+ T-cells have been observed to still produce HIV virus, 
even years after the initiation of HAART. Although the GIT is well 
vascularised and ART drugs should be bioavailable, high levels of 
multidrug-resistant proteins, also named “toxin pumps” (such as 
P-glycoprotein), are expressed on the apical surface of columnar 
epithelial cells of both the small and large intestine. It is speculated 
that these multidrug-resistant proteins, have specificity for protease 
inhibitors and nucleoside analogs and may reduce the local 
concentration of ART drugs to infected cells in the GIT, thus allowing 
the virus to slowly replicate and limit reconstitution of CD4+ T-cells.2 
Ongoing local inflammation in the GIT maybe a second reason 
for the failure of PLWH on HAART to reconstitute CD4+ T-cells. 
Local immune activation has been shown to be associated with 
fibrosis of the lymphoid architecture in peripheral lymph nodes, 
which in turn influences the degree of peripheral blood CD4+ T-cell 
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reconstitution following the initiation of HAART. Recent findings also 
suggest that the fibrotic deposition of collagen also occurs in the 
GIT Peyer’s patches, even during the acute phase of HIV infection. 
The degree of architectural damage of the Peyer’s patches predicts 
GIT CD4+ T-cell depletion after HAART. Although HAART reduces GIT 
immune activation, it is thought that the ability of the remaining (but 
damaged) lymphoid to support significant CD4+ T-cell reconstitution 
is permanently damaged.2 As many as 30% of PLWH on HAART, fail 
to reconstitute CD4+ T-cells, despite HIV-viremia control, and are 
described as immunologically-nonresponders (INRs). INRs have an 
increased risk of HIV/ AIDS progression.11
Plasma citrulline: A biomarker of enterocyte mass in 
PLWH?
Plasma or serum citrulline assays have recently emerged as being 
the best tool in assessing enterocyte mass, irrespective of the 
aetiology of the intestinal mucosal disease. Citrulline is the metabolic 
product of glutamine, and its related amino acids, and arginine, and 
is specifically synthesised by small bowel enterocytes. Citrulline 
has been validated for quantitative enterocyte assessment in villous 
atrophy disease. Citrulline plasma levels are not influenced by 
nutritional status, level of hypoalbuminaemia, or inflammatory status. 
The only limitation in interpreting plasma levels is the presence of 
significant renal failure (creatinine clearance of < 30 ml/min) because 
citrulline is metabolised into arginine in the proximal convoluted 
tubules in the kidneys. A recent study12 reported that plasma 
citrulline assays were a reliable indicator of severe chronic infectious 
enteropathy in PLWH, and hence a reliable predictor of the need 
for parenteral nutrition (PN) for such cases. A low citrulline level of 
< 10 umol/L is considered an indication for PN, whereas for an 
individual with a citrulline level of > 10 umol/L, enteral route nutritional 
support is recommended. Citrulline is easy to measure through ion-
exchange or reverse-phase liquid chromatography, which could be 
performed in better equipped hospital laboratories.12   
The role of HIV vaccines in enhancing GIT mucosal 
cell immunity
There is some promising evidence which suggests that direct 
surgical introduction of a vaccine, (replication-competent 
recombinant adenovirus {rAd} vectors, specifically rAd5), rather 
than oral gavage, resulted in 100-fold higher transgene expression, 
and which stimulated potent CD8+ T-cell responses in the intestinal 
and systemic compartments. These responses could be further 
enhanced through intramuscular rAd5 injections.13 The activation 
status of CD8+ T-cells is considered to be one of the best predictors 
of HIV disease progression. 5
Conclusion
In conclusion, the better understanding of the pathophysiology 
of HIV enteropathy has contributed to the better management 
of diarrhoea in PLWH. Further research is likely to yield other 
therapeutic approaches which will further facilitate the management 
of diarrhoea and contribute to further improvements in the quality of 
life of PLWH.  
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